Home Featured Page 61

Featured

Latest

220 Patients or 20,000? Clinics Split on Psychedelics’ First Year

Robert Rush: Emergency Scheduling, 7-OH, and the War on Research

Breaking: Compass Files Psilocybin for TRD New Drug Application with FDA

The Problems We Will Be Lucky to Have

Pα+ Psychedelic Bulletin #234: Psychedelics After the Midterms; FDA Answers House Psychedelics Caucus; ICER to Review Compass’ Psilocybin; Terran v. Compass Gets Trial Date

The Illinois CURE Act: Shaping the Future of Psychedelic Policy

Regenerative Economics and Psychedelics: Creating More Connected Leadership

What Does FDA Expect from Lykos’ Next Phase 3 MDMA Study?...

Want to Work in Psychedelics? Here Are 10 Psychedelic Jobs to...

Natural Medicine Advisory Bulletin 13.5: The Birth of a Regulated Psychedelics...

Natural Medicine Advisory Bulletin 13: Peaking in July

Ancestral Teachings for the Psychedelic Renaissance

Build Your Career: Somatic Coaching and Holotropic Fitness

Buddhist Philosophy, Shadow Work, and Integrating a Psychedelic Experience

Breaking: Lykos Lays Off 75% of Staff, Ropes In Pharma Veteran,...

EDITOR PICKS

220 Patients or 20,000? Clinics Split on Psychedelics’ First Year

Robert Rush: Emergency Scheduling, 7-OH, and the War on Research

Breaking: Compass Files Psilocybin for TRD New Drug Application with FDA

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

220 Patients or 20,000? Clinics Split on Psychedelics’ First Year

Robert Rush: Emergency Scheduling, 7-OH, and the War on Research

Breaking: Compass Files Psilocybin for TRD New Drug Application with FDA

The Problems We Will Be Lucky to Have

Pα+ Psychedelic Bulletin #234: Psychedelics After the Midterms; FDA Answers House Psychedelics Caucus; ICER to Review Compass’ Psilocybin; Terran v. Compass Gets Trial Date

The Illinois CURE Act: Shaping the Future of Psychedelic Policy

Regenerative Economics and Psychedelics: Creating More Connected Leadership

What Does FDA Expect from Lykos’ Next Phase 3 MDMA Study?...

Want to Work in Psychedelics? Here Are 10 Psychedelic Jobs to...

Natural Medicine Advisory Bulletin 13.5: The Birth of a Regulated Psychedelics...

Natural Medicine Advisory Bulletin 13: Peaking in July

Ancestral Teachings for the Psychedelic Renaissance

Build Your Career: Somatic Coaching and Holotropic Fitness

Buddhist Philosophy, Shadow Work, and Integrating a Psychedelic Experience

Breaking: Lykos Lays Off 75% of Staff, Ropes In Pharma Veteran,...

EDITOR PICKS

220 Patients or 20,000? Clinics Split on Psychedelics’ First Year

Robert Rush: Emergency Scheduling, 7-OH, and the War on Research

Breaking: Compass Files Psilocybin for TRD New Drug Application with FDA

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY